Acute coronary syndromes without ST segment elevation (NSTE-ACS) represent a very heterogeneous group of diseases.
According of myocardial necrosis markers we can diagnose an unstable angina (biomarkers negative) or NSTE myocardial
infarction (biomarkers positive). Due to frequent presence of unstable atherosclerotic plaque and intracoronary
thrombus (in the first phase form by activated platelets), antiplatelet therapy is a crucial component of complex pharmacological
approach in NSTE-ACS patients. This article presents a review of different antiplatelet agents and their use
in accordance with current therapeutic guidelines.